230 related articles for article (PubMed ID: 30897127)
1. Cyclosporine A trough concentrations are associated with acute GvHD after non-myeloablative allogeneic hematopoietic cell transplantation.
de Kort EA; de Lil HS; Bremmers MEJ; van Groningen LFJ; Blijlevens NMA; Huls G; Brüggemann RJM; van Dorp S; van der Velden WJFM
PLoS One; 2019; 14(3):e0213913. PubMed ID: 30897127
[TBL] [Abstract][Full Text] [Related]
2. Impact of cyclosporine A concentration on acute graft-vs-host disease incidence after haploidentical hematopoietic cell transplantation.
Stocker N; Duléry R; Battipaglia G; Brissot E; Médiavilla C; Sestili S; Paviglianiti A; Ledraa T; Mohty R; Bazarbachi A; Belhocine R; Vekhoff A; Ruggeri A; Mohty M; Malard F
Eur J Haematol; 2019 Jul; 103(1):10-17. PubMed ID: 30958904
[TBL] [Abstract][Full Text] [Related]
3. Impact of cyclosporine-A concentration in T-cell replete haploidentical allogeneic stem cell transplantation.
Yang X; Yang S; Sun A; Qiu H; Tang X; Han Y; Wu D
Clin Transplant; 2018 Apr; 32(4):e13220. PubMed ID: 29493007
[TBL] [Abstract][Full Text] [Related]
4. The safety and efficacy of acute graft-versus-host disease prophylaxis with a higher target blood concentration of cyclosporine around 500 ng/mL.
Machishima T; Kako S; Wada H; Yamasaki R; Ishihara Y; Kawamura K; Sakamoto K; Sato M; Ashizawa M; Terasako K; Kimura S; Kikuchi M; Nakasone H; Kanda J; Yamazaki R; Nishida J; Kanda Y
Clin Transplant; 2013; 27(5):749-56. PubMed ID: 24033855
[TBL] [Abstract][Full Text] [Related]
5. Impact of cyclosporine-A concentration on the incidence of severe acute graft-versus-host disease after allogeneic stem cell transplantation.
Malard F; Szydlo RM; Brissot E; Chevallier P; Guillaume T; Delaunay J; Ayari S; Dubruille V; Le Gouill S; Mahe B; Gastinne T; Blin N; Saulquin B; Harousseau JL; Moreau P; Mohty M
Biol Blood Marrow Transplant; 2010 Jan; 16(1):28-34. PubMed ID: 20053329
[TBL] [Abstract][Full Text] [Related]
6. Relationship between CsA trough blood concentration and severity of acute graft-versus-host disease after paediatric stem cell transplantation from matched-sibling or unrelated donors.
Martin P; Bleyzac N; Souillet G; Galambrun C; Bertrand Y; Maire PH; Jelliffe RW; Aulagner G
Bone Marrow Transplant; 2003 Oct; 32(8):777-84. PubMed ID: 14520421
[TBL] [Abstract][Full Text] [Related]
7. Association between calcineurin inhibitor blood concentrations and outcomes after allogeneic hematopoietic cell transplantation.
Ram R; Storer B; Mielcarek M; Sandmaier BM; Maloney DG; Martin PJ; Flowers ME; Chua BK; Rotta M; Storb R
Biol Blood Marrow Transplant; 2012 Mar; 18(3):414-22. PubMed ID: 21875504
[TBL] [Abstract][Full Text] [Related]
8. Toward optimization of cyclosporine concentration target to prevent acute graft-versus-host disease following myeloablative allogeneic stem cell transplant.
Kwan ACF; Blosser N; Ghosh S; Leyshon C; Dersch-Mills D; Puckrin R; Duggan P; Zepeda V; Savoie L; Stewart D; Storek J; Jamani K
Clin Transplant; 2022 Aug; 36(8):e14732. PubMed ID: 35606904
[TBL] [Abstract][Full Text] [Related]
9. Cyclosporine levels > 195 μg/L on day 10 post-transplant was associated with significantly reduced acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.
Bianchi M; Heim D; Lengerke C; Halter J; Gerull S; Kleber M; Tsakiris DA; Passweg J; Tzankov A; Medinger M
Ann Hematol; 2019 Apr; 98(4):971-977. PubMed ID: 30542943
[TBL] [Abstract][Full Text] [Related]
10. Analysis of factors affecting initial cyclosporine level and its impact on post transplant outcomes in acute leukemia.
Gupta A; Punatar S; Gawande J; Mathew L; Kannan S; Khattry N
J Cancer Res Ther; 2017; 13(6):981-988. PubMed ID: 29237963
[TBL] [Abstract][Full Text] [Related]
11. Favorable outcomes of tacrolimus compared with cyclosporine A for GVHD prophylaxis in HSCT for standard-risk hematological diseases.
Nasu R; Nannya Y; Shinohara A; Ichikawa M; Kurokawa M
Ann Hematol; 2014 Jul; 93(7):1215-23. PubMed ID: 24590535
[TBL] [Abstract][Full Text] [Related]
12. Impact of early cyclosporine A levels on acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation using in vivo T-cell depletion.
Nikoloudis A; Buxhofer-Ausch V; Aichinger C; Binder M; Hasengruber P; Kaynak E; Wipplinger D; Milanov R; Strassl I; Stiefel O; Machherndl-Spandl S; Petzer A; Weltermann A; Clausen J
Cytotherapy; 2024 May; 26(5):490-497. PubMed ID: 38385908
[TBL] [Abstract][Full Text] [Related]
13. Cyclosporine in combination with mycophenolate mofetil versus methotrexate for graft versus host disease prevention in myeloablative HLA-identical sibling donor allogeneic hematopoietic cell transplantation.
Hamilton BK; Rybicki L; Dean R; Majhail NS; Haddad H; Abounader D; Hanna R; Sobecks R; Duong H; Hill BT; Copelan E; Bolwell B; Kalaycio M
Am J Hematol; 2015 Feb; 90(2):144-8. PubMed ID: 25353395
[TBL] [Abstract][Full Text] [Related]
14. Premature cyclosporine cessation and TBI-containing conditioning regimen increase the risk of acute GvHD in children undergoing unrelated donor hematopoietic stem cell transplantation.
Szmit Z; Kałwak K; Król A; Mielcarek-Siedziuk M; Salamonowicz M; Frączkiewicz J; Ussowicz M; Owoc-Lempach J; Gorczyńska E
Adv Clin Exp Med; 2019 Sep; 28(9):1185-1192. PubMed ID: 31430073
[TBL] [Abstract][Full Text] [Related]
15. Achievement of target cyclosporine concentrations as a predictor of severe acute graft versus host disease in children undergoing hematopoietic stem cell transplantation and receiving cyclosporine and methotrexate prophylaxis.
Punnett A; Sung L; Price V; Das P; Diezi M; Doyle J; Dupuis LL
Ther Drug Monit; 2007 Dec; 29(6):750-7. PubMed ID: 18043472
[TBL] [Abstract][Full Text] [Related]
16. Higher therapeutic CsA levels early post transplantation reduce risk of acute GVHD and improves survival.
Rogosheske JR; Fargen AD; DeFor TE; Warlick E; Arora M; Blazar BR; Weisdorf DJ; Brunstein CG
Bone Marrow Transplant; 2014 Jan; 49(1):122-5. PubMed ID: 24037024
[TBL] [Abstract][Full Text] [Related]
17. Transplantation from matched siblings using once-daily intravenous busulfan/fludarabine with thymoglobulin: a myeloablative regimen with low nonrelapse mortality in all but older patients with high-risk disease.
Russell JA; Duan Q; Chaudhry MA; Savoie ML; Balogh A; Turner AR; Larratt L; Storek J; Bahlis NJ; Brown CB; Quinlan D; Geddes M; Zacarias N; Daly A; Duggan P; Stewart DA
Biol Blood Marrow Transplant; 2008 Aug; 14(8):888-95. PubMed ID: 18640572
[TBL] [Abstract][Full Text] [Related]
18. Cyclosporine A (CsA) 2-h concentrations vary between patients without correlation to graft-versus-host disease after allogeneic haematopoietic stem cell transplantation.
Barkholt L; Remberger M; Bodegård H; Ringdén O; Böttiger Y
Bone Marrow Transplant; 2007 Oct; 40(7):683-9. PubMed ID: 17660840
[TBL] [Abstract][Full Text] [Related]
19. A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis.
Gooptu M; Kim HT; Ho VT; Alyea EP; Koreth J; Armand P; Ritz J; Nikiforow S; Glotzbecker BE; Nageshwar P; Soiffer RJ; Antin JH; Cutler CS
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1733-1740. PubMed ID: 29555313
[TBL] [Abstract][Full Text] [Related]
20. Neurologic Complications of the Central Nervous System after Allogeneic Stem Cell Transplantation: The Role of Transplantation-Associated Thrombotic Microangiopathy as a Potential Underreported Cause.
Sala E; Neagoie AM; Lewerenz J; Saadati M; Benner A; Gantner A; Wais V; Döhner H; Bunjes D
Transplant Cell Ther; 2024 Jun; 30(6):586.e1-586.e11. PubMed ID: 38508452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
